MDS 2023

Implementing advances in the diagnosis and treatment of movement disorders across the globe 1:31
Implementing advances in the diagnosis and treatment of movement disorders across the globe
Francisco Cardoso • 28 Aug 2023
Foslevodopa/foscarbidopa improves nocturia symptoms in patients with Parkinson’s disease 1:19
Foslevodopa/foscarbidopa improves nocturia symptoms in patients with Parkinson’s disease
K. Ray-Chaudhuri • 29 Aug 2023
Growing controversies and advancements in movement disorders care 2:24
Growing controversies and advancements in movement disorders care
Francisco Cardoso • 28 Aug 2023
Advances in alpha-synuclein as a biomarker for Parkinson’s disease 2:19
Advances in alpha-synuclein as a biomarker for Parkinson’s disease
Tiago Outeiro • 28 Aug 2023
The need for increased awareness and education for movement disorders 1:08
The need for increased awareness and education for movement disorders
Francisco Cardoso • 28 Aug 2023
The impact of genetics on Parkinson’s disease diagnosis and treatment options 1:15
The impact of genetics on Parkinson’s disease diagnosis and treatment options
Prashanth Kukkle • 27 Aug 2023
The future of Parkinson’s disease: defining the disease, biomarkers and targeted treatments 0:48
The future of Parkinson’s disease: defining the disease, biomarkers and targeted treatments
Oscar Gershanik • 28 Aug 2023
Embracing online content to reach a global audience 1:13
Embracing online content to reach a global audience
Francisco Cardoso • 28 Aug 2023
New hopes for the treatment of Parkinson’s disease 1:22
New hopes for the treatment of Parkinson’s disease
Gennaro Pagano • 29 Aug 2023
Shifting the focus on Parkinson’s disease research: looking beyond the dopamine deficit 1:09
Shifting the focus on Parkinson’s disease research: looking beyond the dopamine deficit
Santiago Perez Lloret • 27 Aug 2023
The role of risvodetinib in the treatment of Parkinson’s disease & other CNS diseases 1:40
The role of risvodetinib in the treatment of Parkinson’s disease & other CNS diseases
Milton Werner • 29 Aug 2023
Update on the ADOPTION study: opicapone in Parkinson’s disease 1:43
Update on the ADOPTION study: opicapone in Parkinson’s disease
Joaquim Ferreira • 29 Aug 2023
The importance of partnerships between healthcare professionals and Parkinson’s disease patients 1:42
The importance of partnerships between healthcare professionals and Parkinson’s disease patients
Alfonso Fasano • 7 Sep 2023
The value of alpha-synuclein as a putative target for therapeutic intervention in synucleinopathies 3:01
The value of alpha-synuclein as a putative target for therapeutic intervention in synucleinopathies
Tiago Outeiro • 28 Aug 2023
Challenges faced in the clinical assessment of non-motor features in Parkinson’s disease 3:31
Challenges faced in the clinical assessment of non-motor features in Parkinson’s disease
K. Ray-Chaudhuri • 29 Aug 2023
Evaluation of cases of psychosis from opicapone safety data 4:03
Evaluation of cases of psychosis from opicapone safety data
Luis Guedes • 29 Aug 2023
The content of VJNeurology is intended for healthcare professionals